Kesonotide is a first-in-class, dual-action drug that targets both cancer cells and their tumour microenvironment (TME), addressing a major cause of cancer recurrence and resistance.
It blocks the protein vimentin, disrupting cancer growth and TME support while sparing healthy immune cells. Kesonotide has shown safety and oral bioavailability in a pilot prostate cancer study (12 patients).
The upcoming ADVICE Phase Ib/IIa trial will test kesonotide in up to 80 patients with advanced solid cancers, including brain tumours. Its unique mechanism and ability to cross the blood-brain barrier position kesonotide as a promising, transformative therapy for solid cancers.
Developments in the nanoparticle world and how to determine and predict chemo benefits in MHSPC
